Objective. The mechanism of anti-inflammatory effects of methotrexate (MTX ) at low dose may relate to a decrease in availability of the purine precursor or it may depend on accumulation of 5-aminoimidazole-4-carboxamide (AICAR) and the anti-inflammatory nucleoside adenosine. The aim of this study was to evaluate the possible mechanism of action by analysis of changes in blood concentrations of purine and pyrimidine metabolites during MTX treatment.
Methotrexate (MTX ), originally applied for the treatlarly at the step of methylation of dUMP into dTMP ment of cancer [1] , is now widely used as an antiby thymidylate synthetase, caused disruption of DNA inflammatory and immunosuppressive agent in the treatsynthesis and inhibition of the proliferation of cells ment of rheumatoid arthritis (RA) and other chronic involved in the inflammatory process in the joints. inflammatory disorders [2] . The mechanism of action However, it has been noted in some experimental models of MTX treatment in RA requires detailed that changes induced by MTX in de novo purine synre-examination since the dose used is several orders of thesis included considerable accumulation of intermagnitude lower than in the treatment of cancer. A mediates such as 5-aminoimidazole-4-carboxamide well-established anti-proliferative effect of MTX on cells ribonucleotide (AICAR) resulting from inhibition of involved in autoimmune reactions due to inhibition of the AICAR transformylase reaction [4] . This in turn, dihydrofolate reductase and folate-dependent transvia inhibition of adenosine deaminase and AMP deaminmethylations was proposed initially to explain the mechase or activation of ecto-5∞-nucleotidase, could lead to anism of action [3] . According to this concept, inhibition an increased production of the anti-inflammatory and of mononucleotide precursors of nucleic acids, particuimmunosuppressive adenosine [5] [6] [7] Figure 1A shows concentrations of adenosine at different lymphocytes [11] , induction of apoptosis and clonal times after MTX administration. No changes in venous deletion of activated peripheral T lymphocytes [12] . All blood adenosine concentration were observed during these changes could be vital for the anti-inflammatory MTX treatment compared to its initial concentration of effect of MTX, but may be also secondary to changes~7 0 n. Figure 1B shows changes in uric acid concenin nucleotide metabolism of the cell. Since clinical data tration during MTX treatment. A significant decrease concerning the biochemical events associated with MTX was observed shortly after MTX administration. The administration are limited, the aim of the present study level remained low after 24 h and returned to prewas to evaluate possible mechanisms of action of lowtreatment values on day 7. The hypoxanthine concentradose MTX by the determination of changes in blood tion (Fig. 1C ) decreased likewise immediately after nucleotide metabolite levels in RA patients treated with MTX administration, remained low for 2 days and MTX at the initial phase of chronic treatment.
returned to pre-treatment values after 7 days, as for uric acid. Blood uridine concentration ( Fig. 1D) decreased Methods 24 h after MTX administration, remained low after 48 h and returned to pre-treatment values after 7 days. Patients Figure 2 shows chromatograms of the nucleotides in Seven patients (age 30-60 yr, all women) diagnosed with blood extracts at different stages after MTX administra-RA stage II/III (according to ARA criteria) and qualition. As may be seen, no formation of ZTP in the fied for MTX treatment were recruited to the study. patient's erythrocytes was detected. Blood samples colVenous blood samples were collected 1 day before, lected from a patient with hypoxanthine-guanine phosimmediately (1 h) before and at different times (2 h, phoribosyltransferase deficiency analysed together with 24 h, 48 h, 1 week) after a first 7.5 mg oral dose of MTX the RA patients' extracts showed a prominent peak of starting prolonged weekly treatment with this drug.
ZTP, which is a typical metabolic change in this inherited Blood (0.75 ml ) was immediately mixed with an equal disorder. The latter confirmed that the lack of ZTP was volume of 1.3  perchloric acid as previously described, not due to co-elution with either ATP or GTP, or lack and samples were frozen in liquid nitrogen and mainof erythrocyte enzymatic capacity to produce ZTP. tained at −70°C until analysis.
Discussion

Analysis of nucleotides, nucleosides and bases by HPLC Samples were thawed, mixed and centrifuged for 3 min
This study demonstrates a significant decrease in purine at 13 000 g in a microcentrifuge. Supernatants were and pyrimidine metabolite concentrations immediately collected and neutralized with 3  K 3 PO 4 . After a after low-dose MTX administration in patients with subsequent centrifugation step (13 000 g, 1 min), potas-RA. The marked decreases in uric acid and hypoxansium perchlorate precipitate was removed and the thine concentrations observed could be an indication of supernatant was injected onto the chromatograph.
inhibited purine synthesis, which is a well-established Concentrations of adenosine, hypoxanthine, uric acid mechanism of action of MTX in cancer. On the other and uridine were evaluated using reversed-phase HPLC hand, no change in adenosine concentration and the as described in detail previously together with informaabsence of ZTP formation in the erythrocytes shown in tion about the reproducibility and recovery of the prothis study do not support the recently proposed AICAR/ cedure [13, 14] . The reproducibility of sample extraction adenosine role in the mechanism of action of MTX. and the analysis procedure in the current series of Inhibition of purine nucleotide precursor synthesis by analyses, expressed as the coefficient of variation, was MTX is a primary effect of this drug, but it has been 15.8% for adenosine and <5% for all other metabolites clearly confirmed only after high-dose MTX administrastudied. Erythrocyte nucleotide concentrations [ATP, tion in the treatment of cancer [16 ] . Our study provides UTP, GTP, CTP, AICAR-triphosphate (ZTP)] were evidence that inhibition of purine synthesis and the measured by anion-exchange HPLC [15] . UV-absorbing consequent fall in its blood concentrations could also peaks in both the reversed-phase and anion-exchange be important after low-dose MTX administration in systems were quantified from the absorbance at 254 nm patients with RA. However, the degree of purine synrelative to standards of known concentrations. Peak thesis inhibition or specific processes affected after lowidentity was confirmed by retention time coupled with dose MTX treatment must be different. Unlike highanalysis of diode array detector spectra.
dose MTX in malignancies, no significant cytotoxic effect occurred and blood uric acids were lowered not Data presentation and analysis elevated. The gross elevation of uric acid which can occur due to excessive nucleic acid degradation from Results are presented as the mean ± ... Statistical comparison was performed using analysis of variance dead cells after high-dose MTX in cancer is well documented [17] . An alternative explanation for the uric for repeated measures followed by Student-NewmanKeuls test with P <0.05 considered as a significant acid-lowering effect we noted in RA could be its increased urinary excretion, but parallel falls in hypoxandifference. thine concentration support the inhibition of purine detectable in the erythrocytes as ZTP [18] . No accumulation of ZTP was observed at any stage of MTX treatsynthesis as the mechanism. However, a decrease in hypoxanthine concentration could also be caused by its ment in our patients, nor were we able to show any direct effects of MTX on blood adenosine concentration. increased salvage, but this again indicates inhibition of de novo synthesis by MTX which would be the most These findings argue against the AICAR/adenosinemediated hypothesis of action of MTX which was likely reason for that. Further studies focused on uric acid clearance in RA patients on low-dose MTX are developed based on animal and cell culture studies [6, 7] . However, the possibility cannot be excluded that necessary to clarify this problem.
An alternative explanation for our proposal of nuclelocalized changes in adenosine concentration may occur in the joint, not mediated by AICAR and without otide precursor starvation by low-dose MTX focuses on adenosine as the effector metabolite in RA [6, 7] . It was systemic changes being noted. A decrease in synovial fluid adenosine has been described in patients with RA suggested that this increase in adenosine production is mediated by accumulation of the purine de novo interwithout changes in blood concentration [19] . This indicates the potential significance of changes in synovial mediate AICAR and its dephospho product 5-aminoimidazole-4-carboxamide ribonucleoside (AICAr). If the adenosine metabolism in RA. However, changes in synovial fluid adenosine resulting from pharmacological animal model used is applicable to humans, irrespective of in which part of the body AICAR or AICAr accumutreatment such as MTX still need to be established. Consequently, the adenosine hypothesis remains very lation occurs, we should have been able to observe formation of the AICAR triphosphate ZTP in the attractive, but requires further research to confirm its applicability to humans treated with low-dose MTX. circulating erythrocytes. Excessive AICAR accumulation in inherited hypoxanthine-guanine phosphoribosylEvaluation of the effect of MTX on ecto-5∞-nucleotidase expression appears to be particularly important in view transferase deficiency (Lesch-Nyhan syndrome) is F. 2. Anion-exchange HPLC chromatograms of blood extracts from a patient with rheumatoid arthritis at different times after methotrexate (MTX ) administration and from a patient with hypoxanthine-guanine phosphoribosyltransferase (HGPRT ) deficiency. An accumulation of ZTP, typical for HGPRT deficiency, was not observed after MTX administration. typically noted within a month of treatment [26 ] . 
